The Pharmacist's Role in Deterring Opioid Abuse

Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.

Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.

In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.

Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.

In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.

Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.

At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.

Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.